[Biosimilars in inflammatory bowel disease]

Z Gastroenterol. 2016 Nov;54(11):1217-1222. doi: 10.1055/s-0042-117648. Epub 2016 Oct 6.
[Article in German]


After the expiry date of the patent protection for Infliximab in 2013, the biosimilar CT‑P13 was approved for indications in Crohn's disease and ulcerative colitis in adults as well as in children. The approval has been based on two randomized clinical studies indicating equivalence for the biosimilar with regard to pharmacokinetics, efficacy, as well as side-effects. The clinical experience since, in addition to multiple non-randomized studies, indicate a comparable efficacy and immunogenicity of the Infliximab biosimilar CT-P13 in inflammatory bowel disease. Thus, the introduction of the biosimilar as primary therapy seems to be justified. Tight monitoring of the safety of biosimilars with regard to efficacy and side effects has to be ensured.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Biosimilar Pharmaceuticals / administration & dosage*
  • Biosimilar Pharmaceuticals / adverse effects
  • Drug Approval / methods*
  • Drug Substitution / trends*
  • European Union
  • Evidence-Based Medicine*
  • Humans
  • Inflammatory Bowel Diseases / diagnosis
  • Inflammatory Bowel Diseases / drug therapy*
  • Randomized Controlled Trials as Topic
  • Therapeutic Equivalency
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Biosimilar Pharmaceuticals
  • CT-P13